MAXITROL OINTMENT HEALIT XYLOAID XYLOAID CORTISPORIN LIDOSPORIN OTOSPORIN POLYFAX PLUS POLYFAX POLYFAX POLYFAX POLYFAX NOVOFAX NOVOFAX MEDITROL MYCITRACIN PLUS POLYVEE POLYVEE ORBATROL ORBATROL BIOPRED OTOCAINE POLYDEX POLYSPORE-HC POLYSPORE-HC STERIBIOL OCUTROL SANTIROL BACIMIX BACIMIX ZYLOSPORE BIOFAX CITRALIN GERMINIL GERMINIL GERMINIL XINOXY DOVATE DOVATE OPHTH-NEODEX BACIMIX-P POLYTROL POLDEC POLYCAINE POLYMIXIN POLYZAF POLYZAF PRIMAFAX PRIMAFAX POLITE POLITE POLITE POLITE POLYTRACIN OCUFLUR PN TRANCE GERMINIL PLUS POLYGYNAX DRAPED POLYAID PLANODERM POLYMYX MULTIFAX TRIMIN ZEFTAC POLYREX POLYREX DANAFEX BECNOT BECNOT BACISTAT MAXITROL DROPS POLYBACK ZE FAX POLYWAX

Dose: 15000 to 30000 units/kg/day
Single Dose: 22000 (22500)
Frequency: 24 hourly
Route: IM
Instructions: This should be reduced in the presence of renal impairment.The dosage may be divided and given at either 4 or 6 hour intervals.

Dose: 0.25 mg/kg
Single Dose: 0.25 (0.25)
Frequency: 24 hourly
Route: Intrathecal
Instructions:

Dose: 0.33 mg/kg
Single Dose: 0.33 (0.33)
Frequency: 24 hourly
Route: Intrathecal
Instructions: For above 2 yrs children

. It is of Semi Synthetic origin and belongs to Decapeptide. It belongs to Antibiotic (Cell Wall) pharmacological group on the basis of mechanism of action and also classified in Antibiotics pharmacological group.The Molecular Weight of Polymyxin B (Sulphate) is 1203.00. Its pKa is 8.9.

Polymyxin B (Sulphate) is contraindicated in conditions like Hypersensitivity to the drug.

The severe or irreversible adverse effects of Polymyxin B (Sulphate), which give rise to further complications include Convulsions, Coma, Psychosis, Hypersensitivity reactions, Neuromuscular blockage.Polymyxin B (Sulphate) produces potentially life-threatening effects which include Nephrotoxicity, Neurotoxicity, Hematuria, Respiratory paralysis. which are responsible for the discontinuation of Polymyxin B (Sulphate) therapy.The symptomatic adverse reactions produced by Polymyxin B (Sulphate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Drowsiness, Ataxia, Nausea, Vomiting, Blurred vision, Confusion, Urticaria, Flushing, Muscle weakness, Paresthesias, Proteinuria, Reaction at injection site, Azotemia.

Polymyxin B (Sulphate) is primarily indicated in conditions like Bacteremia, Meningitis, Superficial infections, Urinary tract infection, and can also be given in adjunctive therapy as an alternative drug of choice in Joint infections, Skin infections.

Polymyxin B (Sulphate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcuronium (Cl)Amikacin (Sulphate)Amphotericin BAtracurium (Besylate)Botulinum B ToxinBotulinum Toxin Type ACapreomycinIncreased risk of nephrotoxicity when capreomycin given with Polymyxin B (Sulphate)Cephalothin (Na)Distigmine (Br)Floxacillin (Na)NeostigmineNetilmicin (Sulphate)PipercuroniumQuinidine may enhance the effect of pipercuronium.Pyridostigmine (Br)Rocuronium (Br)StreptomycinPolymyxin B (Sulphate) may increase the actions and side effects of Streptomycin.TobramycinVecuronium (Br) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Oint, Powder Store Below 40°C. Protect from Heat.

Before initiating therapy with polymyxin B determine baseline kidney function. Serum concentration must be monitored regularly during treatment. It should be used with caution in patients with renal impairment, mysthania gravis or other condition of neuromuscular disease, in patients known to have hypersensitivity reactions, in pulmonary disease, if sign of respiratory distress or nephrotoxicity occur, the drug should be discontinued. Take appropriate measures in case of secondary infection.